Pfizer Licenses Seattle Genetics’ Antibody-Drug Conjugate Technology
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 1 (Table of Contents)
Published: 24 Jan-2011
DOI: 10.3833/pdr.v2011.i1.1424 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Pfizer has entered into a collaboration with Seattle Genetics to license the company’s antibody-drug conjugate (ADC) technology to develop antibodies against a single oncology target...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS